Paradigm Biopharmaceuticals (PAR) Stock Statistics & Valuation Metrics

Paradigm Biopharmaceuticals has a market cap or net worth of AU$150.31M. The enterprise value is AU$101.96M.

Paradigm Biopharmaceuticals has 411,797,330 shares outstanding. The number of shares has decreased by -2.65% in one year.

Paradigm Biopharmaceuticals’s return on equity (ROE) is -0.89 and return on invested capital (ROIC) is -79.54%.

The current PE Ratio of Paradigm Biopharmaceuticals is ―. Paradigm Biopharmaceuticals’s PEG ratio is 0.07.

In the last 12 months, Paradigm Biopharmaceuticals had revenue of 52.12K and earned -18.77M in profits. Earnings per share was -0.06.

In the last 12 months, operating cash flow was -15.99M and capital expenditures 3.00, giving a free cash flow of -15.99M billion.

Paradigm Biopharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Paradigm Biopharmaceuticals upcoming earnings date is Feb 25, 2026, TBA (Confirmed).

Paradigm Biopharmaceuticals as a current ratio of 7.46, with Debt / Equity ratio of 0.53%

In the past 12 months, Paradigm Biopharmaceuticals has paid -6.53M in taxes.

Paradigm Biopharmaceuticals EV to EBITDA ratio is -3.13, with an EV/FCF ratio of -4.95.

Paradigm Biopharmaceuticals has AU$16.82M in cash and marketable securities with AU$5.48K in debt, giving a net cash position of AU$16.81M billion.

Gross margin is -13.34%, with operating margin of -43910.60%, and net profit margin of -36014.48%.

The average price target for Paradigm Biopharmaceuticals is AU$0.65, which is 11.43% higher than the current price. The consensus rating is Moderate Buy